Quick Answer
Lyra Therapeutics, Inc. reported Net Income Loss of -$28.92 million for the year ending 2025.
- Lyra Therapeutics, Inc. showed an increase of +69.0% in Net Income Loss from 2024 to 2025.
- This data is from Lyra Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 7 years of available data (2019 to 2025), Lyra Therapeutics, Inc.'s Net Income Loss has declined by 77.4%.
- Historical annual values: Fiscal year 2025: -$28.92 million | Fiscal year 2024: -$93.44 million | Fiscal year 2023: -$62.68 million | Fiscal year 2022: -$55.28 million | Fiscal year 2021: -$43.51 million | Fiscal year 2020: -$22.13 million | Fiscal year 2019: -$16.31 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: